Rapport's epilepsy drug RAP-219 clears Phase 2 bipolar mania trial

· Health · United States

Rapport Therapeutics said its investigational oral drug RAP-219 cleared a mid-stage trial in bipolar mania, narrowly hitting the main goal despite what some analysts described as low expectations. The drug, licensed from Johnson & Johnson, dials down the effect of AMPA receptors and had been in development for epilepsy. Success paves the way for registrational studies slated to start next year, and analysts said the result could help Rapport tap a market opportunity worth more than a billion dollars. A win in bipolar mania would broaden the drug beyond its original epilepsy target and give the company a second shot at a large neuropsychiatry indication.

Why it matters：A surprise mid-stage win in bipolar mania could extend an AMPA-targeting mechanism beyond epilepsy, and the readout will be watched as a test of whether niche neuroscience assets can open billion-dollar psychiatric markets.

Key points

  • RAP-219 was licensed from Johnson & Johnson and targets AMPA receptors.
  • Registrational studies are slated to start next year.

Sources (original reporting)

More stories from this day